Deworming drug could tame ulcerative colitis, small trial hopes

NCT ID NCT06335160

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding mebendazole, a common deworming medication, to standard mesalamine therapy can improve symptoms in people with mild-to-moderate ulcerative colitis. 46 adults will take mebendazole or a placebo twice daily for 6 months. Researchers will measure changes in disease activity and blood markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mebendazole (a deworming medication)

What this could lead to

If it works, this could point toward a new, affordable add-on treatment for ulcerative colitis.

What could go wrong

This is a small, early-phase trial with only 46 people. Mebendazole is not a standard colitis drug, so it may not work or could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tanta Unuversity

    RECRUITING

    Tanta, 34518, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••